Clayton Foundation For Research is located in Houston, TX. The organization was established in 1966. According to its NTEE Classification (H99) the organization is classified as: Medical Research N.E.C., under the broad grouping of Medical Research and related organizations. As of 12/2023, Clayton Foundation For Research employed 52 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Clayton Foundation For Research is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Clayton Foundation For Research generated $11.0m in total revenue. This represents a relatively dramatic decline in revenue. Over the past 5 years, the organization has seen revenues fall by an average of (8.6%) each year. All expenses for the organization totaled $10.8m during the year ending 12/2023. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
THE PRIMARY MISSION IS TO CONDUCT MEDICAL RESEARCH IN CONJUNCTION WITH HOSPITALS FOR THE PURPOSE OF DISCOVERING THE CAUSE, PREVENTION AND CURE OF DISEASES FOR THE BENEFIT OF MANKIND.
Describe the Organization's Program Activity:
Part 3 - Line 4a
A RESEARCH PROJECT AT BAYLOR COLLEGE OF MEDICINE IN GENE AND PROTEIN THERAPY FOCUSES ON INAPPROPRIATE CELL DIVISION AND CELL DEATH WITHIN THE HUMAN BODY. MUCH OF THE WORK IS DEVOTED TO INTRAOCULAR ANGIOGENESIS, WITH PARTICULAR ATTENTION TO: 1) THE SIGNALS THAT CONTROL THIS PROCESS, 2) THE DEVELOPMENT OF ANIMAL MODELS OF HUMAN OCULAR DISEASE, AND 3) DEVELOPMENT OF POTENTIAL THERAPIES. NEW TARGETS HAVE BEEN IDENTIFIED AND POTENTIAL THERAPEUTIC AGENTS ARE BEING DEVELOPED AND TESTED FOR THE TREATMENT OF WET AMD, DIABETIC RETINOPATHY, AND RETINOPATHY OF PREMATURITY. PATENT APPLICATIONS HAVE BEEN FILED BY RDF, ONE OF THE FOUNDATION'S SUPPORTING ENTITIES, ON SEVERAL DISCOVERIES ARISING OUT OF THIS RESEARCH. LICENSING EFFORTS BY RDF RESULTED IN A LICENSE TO A COMMERCIAL COMPANY THAT, USING PROJECT TECHNOLOGY, COMPLETED A PHASE I HUMAN CLINICAL TRIAL WITH GENE THERAPY TO TREAT WET AGE-RELATED MACULAR DEGENERATION.
THE CONDUCT OF A LONGSTANDING RESEARCH PROGRAM AT THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE PURPOSE OF WHICH IS TO DESIGN AND DEVELOP NOVEL TARGETED THERAPEUTIC AGENTS THAT TARGET A POWERFUL HUMAN TOXIN TO SPECIFICALLY DESTROY CANCER CELLS FOR THE TREATMENT OF NUMEROUS CANCER TARGETS AND OTHER DISEASE INDICATIONS. A NUMBER OF COLLABORATIONS HAVE BEEN UNDERTAKEN WITH RESEARCHERS AT VARIOUS INSTITUTIONS (E.G., UNIVERSITY OF CALIFORNIA SAN DIEGO). PATENT APPLICATIONS HAVE BEEN FILED BY RESEARCH DEVELOPMENT FOUNDATION (RDF), A TAX EXEMPT SUPPORTING ORGANIZATION OF THE FOUNDATION (SEE SCHEDULE R, PART III), ON MORE THAN TWENTY DISCOVERIES, AND A NUMBER OF PATENTS HAVE BEEN ISSUED. LICENSING EFFORTS HAVE BEEN ONGOING AND HAVE RESULTED IN SEVERAL LICENSES.
A RESEARCH PROGRAM AT BAYLOR COLLEGE OF MEDICINE IN HOUSTON IS DIRECTED TOWARD GLAUCOMA, THE SECOND LEADING CAUSE OF PERMANENT BLINDNESS IN THE WORLD. MORE THAN 3 MILLION AMERICANS LIVE WITH GLAUCOMA, AND IT IS ESTIMATED THAT PERHAPS MILLIONS MORE REMAIN UNDIAGNOSED. THE RESEARCH INCLUDES OPPORTUNITIES TO TREAT INTRAOCULAR PRESSURE (IOP) IN A MORE TARGETED WAY THAT IS INDEPENDENT OF CURRENT MEDICAL THERAPIES. STATE OF THE ART TECHNOLOGIES HAVE BEEN DEVELOPED AND ARE BEING USED TO ANALYZE AND CHARACTERIZE THE MOLECULAR CHANGES ASSOCIATED WITH THE EARLY STAGES OF THE DISEASES. THE RESEARCHERS OBJECTIVE IS THE IDENTIFICATION OF NEW POTENTIAL THERAPIES FOR GLAUCOMA.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Jarred W Sloan Trustee, President, Treasurer | OfficerTrustee | 20 | $274,083 |
Robert M Wallace Trustee, Vice President | OfficerTrustee | 20 | $203,370 |
Lynn P Carter Trustee | Trustee | 8 | $97,315 |
Joan S Dunlap Trustee, Vp, Secretary | OfficerTrustee | 4 | $126,473 |
Brian W Crozier Trustee, Chairman | OfficerTrustee | 5 | $97,315 |
Thomas J Brorby Trustee, Deceased | OfficerTrustee | 5 | $80,872 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $8,075,000 |
Government grants | $0 |
All other contributions, gifts, grants, and similar amounts not included above | $0 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $8,075,000 |
Total Program Service Revenue | $96,250 |
Investment income | $1,938,814 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $143,062 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $790,664 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $11,043,790 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $150,000 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $1,675,787 |
Compensation of current officers, directors, key employees. | $285,441 |
Compensation to disqualified persons | $497,743 |
Other salaries and wages | $2,583,482 |
Pension plan accruals and contributions | $358,217 |
Other employee benefits | $1,174,817 |
Payroll taxes | $198,780 |
Fees for services: Management | $0 |
Fees for services: Legal | $18,571 |
Fees for services: Accounting | $52,329 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $286,997 |
Fees for services: Other | $17,074 |
Advertising and promotion | $0 |
Office expenses | $63,518 |
Information technology | $0 |
Royalties | $0 |
Occupancy | $366,266 |
Travel | $43,557 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $0 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $31,051 |
Insurance | $236,401 |
All other expenses | $133,719 |
Total functional expenses | $10,750,530 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $1,750,906 |
Savings and temporary cash investments | $0 |
Pledges and grants receivable | $0 |
Accounts receivable, net | $245,846 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $200,426 |
Net Land, buildings, and equipment | $2,544,256 |
Investments—publicly traded securities | $101,051,932 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $24,779,102 |
Total assets | $130,572,468 |
Accounts payable and accrued expenses | $7,121,038 |
Grants payable | $0 |
Deferred revenue | $0 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $0 |
Total liabilities | $7,121,038 |
Net assets without donor restrictions | $82,886,840 |
Net assets with donor restrictions | $40,564,590 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $130,572,468 |
Over the last fiscal year, Clayton Foundation For Research has awarded $25,000 in support to 2 organizations.
Grant Recipient | Amount |
---|---|
GEORGETOWN UNIVERSITY PURPOSE: Gen Purpose | $15,000 |
NATIONAL MS SOCIETY PURPOSE: Gen Purpose | $10,000 |